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Objective:Value-based methods are increasingly used to reimburse therapeutic innovation, and the payment-by-
results approach has been proposed for handling interventions with limited therapeutic evidence. Because most
left ventricular assist devices are supported by preliminary efficacy data, we examined the effectiveness data of
the HeartMate (Thoratec Corp, Pleasanton, CA) device to explore the application of the payment-by-
results approach to these devices and to develop a model for handling reimbursements.
Methods: According to our model, after establishing the societal economic countervalue for each month of life
saved, each patient treated with one such device is associated to the payment of this countervalue for every month
of survival lived beyond the final date of estimated life expectancy without left ventricular assist devices. Our
base-case analysis, which used the published data of 68 patients who received the HeartMate device, was run
with a monthly countervalue of V5000, no adjustment for quality of life, and a baseline life expectancy of 150
days without left ventricular assist devices. Sensitivity analysis was aimed at testing the effect of quality of
life adjustments and changes in life expectancy without device.
Results: In our base-case analysis, the mean total reimbursement per patient was V82,426 (range, V0 to
V250,000; N¼ 68) generated as the sum of monthly payments. This average value was close to the current price
of the HeartMate device (V75,000). Sensitivity testing showed that the base-case reimbursement ofV82,426 was
little influenced by variations in life expectancy, whereas variations in utility had a more pronounced impact.
Conclusion: Our report delineates an innovative procedure for appropriately allocating economic resources in
this area of invasive cardiology.In handling therapeutic innovation, value-based methods1-3
are increasingly used to determine reimbursements that are
proportional to the magnitude of the (incremental) clinical
benefit of the innovative treatment. In Europe, threshold
values of cost-effectiveness recognize up to V5000
(monthly countervalue [MCV]) to each month of survival
gained or to each quality-adjusted month gained. Likewise,
yearly thresholds are generally set at approximately
V50,000 to V60,000, $50,000 to $100,000, or £25,000 to
£30,000.2,3
Converting the clinical benefit into an economic counter-
value requires that the typical (incremental) benefit resulting
from the innovative treatment is supported by a sufficient ev-
idence with a reasonably small statistical variability. On the
other hand, many innovative treatments are characterized by
premature therapeutic evidence on their effectiveness, sim-
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Determining reimbursements for innovative treatments
with premature therapeutic evidence is a challenging task
because regulatory agencies tend to be cautious in accept-
ing the claimed degree of incremental benefit, whereas
manufacturers tend to be more optimistic in predicting
the outcome expected from their innovation. One solution
to this controversy is the payment-by-results approach,4-6
wherein reimbursements are not estimated from the magni-
tude of the ‘‘average’’ benefit (as demonstrated in previous
clinical trials) but are determined from the outcomes pro-
spectively observed in individual patients (so that nonre-
sponders generate no payments and responders generate
payments).
Most left ventricular assist devices (LVADs) are currently
supported by scarce data documenting the extent of their in-
cremental benefit.7 Also the analyses on the cost-effective-
ness of these devices tend to give conflicting indications.7
Thus, LVADs are good candidates for the application of
the payment-by-results approach.
Briefly, the payment-by-results approach applied to
LVADs is simply implemented through the monthly pay-
ment of an amount of money equal to MCV for every month
of survival lived by the patient beyond the final date of his or
her life expectancy without an LVAD (predicted at baseline,
ie, before implantation).
In this article, we have used the clinical information al-
ready published on the effectiveness of the HeartMategery c August 2009
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XAbbreviations and Acronyms
AST ¼ additional survival time
bLE ¼ baseline life expectancy
indST ¼ individual survival time
LVAD ¼ left ventricular assist device
MCV ¼ monthly countervalue
(Thoratec Corp, Pleasanton, CA) device to explore the ad-
vantages and the disadvantages in applying the payment-
by-results approach to this type of innovative devices.
MATERIALS AND METHODS
Design
By using published information available on patients who received the
HeartMate device,8 our analysis was aimed at determining the values of re-
imbursement associated with each patient according to the payment-by-re-
sults approach.4,5 The individual survival times (indSTs) after implantation
for the published 68 patients receiving the HeartMate device8 were derived
by a computerized analysis of the original Kaplan–Meier curve.9 In addi-
tion, the 11 survivors at the last time point of the published follow-up (45
months) were assigned an additional survival time (AST), thus resulting
in an overall postimplantation survival of 45 monthsþAST.
The rationale behind our economic calculations was that the payment for
each patient had to correspond to an amount of money equal to MCV for
every month of survival lived by the patient beyond the final date of his
or her life residual expectancy without an LVAD. Our base-case analysis
was developed as follows: MCV ¼ V5000; no adjustment for quality of
life (ie, utility ¼ 1); life expectancy without LVAD predicted at baseline,
ie, before implantation, bLE¼ 150 days or 5 months per patient [according
to Park and colleagues8)]; AST ¼ 12 months.
Clinical Material and Survival Information
The 68 patients treated with the HeartMate device (53 male, 97.1%with
New York Heart Association class IV, mean age of 66 years) have been de-
scribed in detail in the original report.8 For these 68 patients, the indSTs re-
constructed from the original Kaplan–Meier curve have been reported,9
along with information on how these data were extracted from the published
survival curve. The value of AST¼ 12 months, introduced in our base-case
analysis, was determined by extrapolating the published survival curve to
infinity according to the Gompertz method.10,11
Basecase Analysis
First, the data of each of the 68 patients were analyzed according to the
following equation: individual reimbursement ¼ ðindST--bLEÞ3MCV(Eq-
uation 1), where the values of indST and bLE are expressed in months and
monetary parameters are expressed in Euros; individual reimbursement
was set to 0 when bLE> indST. Then, the average of these 68 reimburse-
ments was calculated and its value was finally compared with the true price
of the HeartMate device (currently V75,000).
Sensitivity Analysis
A first series of analyses was carried out by introducing utility as a qual-
ity-of-life adjustment for indSTs. The utility values were drawn from Mos-
kowitz and colleagues,12 who reported a mean utility of 0.809 in LVAD
recipients (with the 1 standard deviation interval ranging from 0.945 to
0.673). In another sensitivity analysis, the value of bLE varied from 6 to
24 months, and in another analysis the value of AST assigned to the 11 sur-
vivors varied over the range from 2 to 36 months. In a further conclusiveThe Journal of Thoracic and Csensitivity analysis, benefits were discounted at 1.5% per year and costs
were discounted at 3% per year. The authors had full access to the data
and take responsibility for its integrity. All authors have read and agree to
the article as written.
RESULTS
The mean reimbursement found in our basecase analysis
of the 68 patients was V82,426 (range, V0 to V250,000).
These 68 values were distributed as shown in Figure 1.
The average value ofV82,426 was close to the current price
of the HeartMate device (V75,000).
Sensitivity testing (Table 1) showed that the basecase
‘‘average’’ reimbursement of V82,426 was little influenced
by variations in bLE; in contrast, the variations in utility had
a more pronounced impact (Table 1).
The information on the 2 sensitivity analyses (assessing
the effect of discounting or changes in AST, respectively)
is not presented in this article because changes in these 2 var-
iables did not introduce anymeaningful change (<15%) into
our estimates of average reimbursement.
DISCUSSION
The most commonly used value-based methods for reim-
bursing innovative drugs or medical devices do not gener-
ally apply the payment-by-results approach but rely on the
evidence that has accumulated about the ‘‘average’’ (or ex-
pected) incremental benefit of the innovative intervention.
Because the growth of cost-effectiveness analysis has paral-
leled the growth of evidence-based medicine, cost-ef-
fectiveness has derived from evidence-based medicine
a methodological attitude favoring ‘‘summary’’ estimates
rather than the assessment of individual patients.
The traditional cost-effectiveness approach based on ‘‘av-
erage’’ effectiveness generally proceeds through 3 steps:
FIGURE 1. Distribution of the 68 values of reimbursement calculated ac-
cording to the payment-by-results approach. The first bar on the left refers to
reimbursements from V0 to V24,999, the second bar refers to reimburse-
ments from V25,000 to V74,999, and so on.ardiovascular Surgery c Volume 138, Number 2 481
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cal effectiveness;
2. decision-making about reimbursements based on the
‘‘average’’ outcome; and
3. prospective application of the reimbursements defined in
step (2) to the future cases of the ‘‘real world.’’
This approach works particularly well when the clinical
evidence is sound mainly because, under these circum-
stances, both the national health system (or third payer)
and the manufacturer are willing to share the same expecta-
tion about the treatment outcome.
In recent times, cases have emerged in which the national
health system and the product manufacturer could not share
the same expectation about the treatment outcome (eg, inter-
feron for multiple sclerosis,13 bortezomib for multiple mye-
loma,14 and ranibizumab for macular degeneration15).
Typically, the manufacturer had the tendency to fully trust
the results of the (preliminary) clinical trials, whereas the na-
tional health system was more cautious and unwilling to
fully accept the outcomes reported by the preliminary trials.
At least in the United Kingdom, these cases have all been
governed using the payment-by-results approach.
LVADs still have a premature body of effectiveness data,7
with the important exception of the HeartMate device.8 For
this reason, in the present economic study the case of the Heart-
Matedevicewas selectedasaworkedexample todevelopapay-
ment-by-results model for the reimbursement of any type of
LVADs and to test this model ex post against the large series
of real cases already available for the HeartMate device.
The value-for-money principle states that the economic
aim of health care systems is to purchase as much health
TABLE 1. Results of the sensitivity analyses in which utility and
baseline life expectancy without left ventricular assist device were
varied
Average reimbursement per patient (N ¼ 68)




patient u ¼ 1.00 u ¼ 0.945*u ¼ 0.809*u ¼ 0.673*
5 mo (or 2.74 QALMsy) V82,426 V77,893 V66,683 V55,473
6 mo (or 3.29 QALMsy) V78,750 V74,419 V63,709 V52,999
8 mo (or 4.38 QALMsy) V72,721 V68,721 V58,831 V48,941
10 mo (or 5.48 QALMsy) V66,912 V63,232 V54,132 V45,032
12 mo (or 6.58 QALMsy) V61,324 V57,951 V49,611 V41,271
15 mo (or 8.22 QALMsy) V53,382 V50,446 V43,186 V35,926
18 mo (or 9.86 QALMsy) V46,324 V43,776 V37,476 V31,176
21 mo (or 11.51 QALMsy) V40,368 V38,147 V32,657 V27,177
24 mo (or 13.15 QALMsy) V34,412 V32,519 V27,839 V23,159
LVAD, left ventricular assist device; u, utility; QALM, quality-adjusted life month.
*Values from Moskowitz and colleagues,12 who reported a mean utility of 0.809 in
LVAD recipients (with the 1 standard deviation interval ranging from 0.945 to
0.673). yBased on a utility of 0.548 before implantation according to Moskowitz
and colleagues.12482 The Journal of Thoracic and Cardiovascular Suras possible, and not to merely purchase drugs or devices.
For example, in the area of oncology, it has recently been
observed that ‘‘spending $2900 per month in lapatinib
(or $100 per day) does not purchase the 1250 mg daily
of the drug, but purchases the progression-free months
gained by the patients as a result of the drug’s efficacy.’’16
Thus, a change in the mental attitude of health profes-
sionals seems to be needed, and this applies particularly to
the area of medical devices. Accordingly, in the field of
LVADs the belief that the money spent on this innovative
treatment is intended to purchase the device should be dis-
couraged because this money actually purchases the survival
gain (resulting from the LVAD in the patient in whom the
device is implanted).
In this framework, our model for the reimbursement of
LVADs has been developed in full accordance to the value-
for-money principle and by giving preference to the pay-
ment-by-results approach because the therapeutic evidence
for all LVADs except the HeartMate device is still limited.
Our proposed procedure has modeled the entire reim-
bursement procedure of LVADs on the basis of only 2 fun-
damental assumptions:
1. The value of bLE (ie, the residual life expectancy without
LVAD in the individual patient concerned): For the pur-
poses of the present study, the best estimate that we found
in the literature was 150 days (according to Park and col-
leagues8), and so this value was introduced in Equation 1
as a uniform parameter for all patients (‘‘population
method’’). Interestingly enough, this point of our proce-
dure can be further improved in prospective patient series
by individualizing the value of bLE (‘‘individualized
method’’) according to the Seattle model;17,18 this indi-
vidualization, however, requires the knowledge of ap-
proximately 20 staging parameters at baseline for each
patient (that were unavailable for the 68 patients who re-
ceived the HeartMate device in the context of our study).
2. The value of MCV (ie, the societal economic countervalue
of 1 month of life gained): Our analysis was run by setting
MCV ¼ V5000, but of course our procedure can be run
using other values of MCV. Higher values of MCV (eg,
V8000) could be used as a means to encourage therapeutic
innovation; this would imply the awareness by decision-
makers that the first V5000 for each quality-adjusted life
month gained represents the standard value-based pay-
ment, whereas those exceeding the threshold of V5000
(eg,V3000) explicitly serve the purpose to support innova-
tion. Experts in health economics have long agreed that
each unit of survival gained should preferably be valued
as a societal average without introducing any adjustment
depending on the patient concerned.5,19-20
It is noteworthy that the above 2 parameters are fully inde-
pendent of the particular type of LVAD implanted in thegery c August 2009
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model is not for the HeartMate device (for which the data of
effectiveness are adequate), but for the other LVADs that are
presently supported by less data regarding their effectiveness.7
It should also be noted that patients with end-stage heart
failure unsuitable for transplantation generate follow-up
costs that are not too dissimilar depending on whether or
not they have received the LVAD.19 Thus, in economic terms
the 2main factors that generate the difference include the cost
of the surgical implantation of the device ($67,000,19 with
year of costing ¼ 2004, which corresponds to V50,000
using the exchange rate of January 2004 reported by the
www.oanda.org website) and the cost of the device itself.7
The payment-by-results approach can be implemented
more easily in countries with a national public health care
system than in countries where private health care prevails.
In fact, most experiences in the area of payment by results
have thus far taken place in the framework of national health
care systems (eg, the reimbursement of bortezomib for mul-
tiple myeloma in the United Kingdom14 and of sorafenib for
hepatocellular carcinoma in Italy; Messori A, personal com-
munication, 2008). Despite that, the payment-by-results ap-
proach has recently attracted the interest of numerous health
care experts in the United States who have contributed to the
debate on this issue.4,19,21
On the one hand, the American health care system is char-
acterized by a degree of heterogeneity that does not facilitate
reimbursements based on value-for-money or payment-by-
results and that favors instead the traditional fee-for-service
approaches; in addition, the natural propensity of American
insurance companies for administrative models of payment
and not for evidence-based methods further complicates
the application of this approach in the United States.
On the other hand, the increasing availability of innovative
high-cost treatments in thehealth caremarketplace emphasizes
the need to devise methods that give more priority to inno-
vative treatments with proven clinical benefit and less priority
to those characterized by uncertain effectiveness. These
methods, which cannot have a merely administrative basis,
tend to force third payers (irrespective of their private or public
nature) to face, on clinical and scientific grounds, the problem
of differentiating between real clinical benefits and potential
benefits and to recognize to innovation an economic counter-
value proportional to the (incremental) clinical benefit.
As a result, a lively debate has been started in the United
States to contrast the pros and the cons of the value-for-
money approach19,21 and to examine the potential areas of
application of the payment-by-results approach.4,21 One im-
portant advantage of LVADs is that, in assessing the effec-
tiveness of these devices, survival is an undisputed end
point for quantifying the benefit.
As new LAVDs other than the HeartMate device enter the
market (eg, Jarvik [Jarvik Heart Inc, New York, NY], Nova-
cor [World Heart Inc, Oakland CA], and Berlin Heart [BerlinThe Journal of Thoracic and CHeart AG, Berlin, Germany] devices), a difficult question
will be posed to decision makers because a) not reimbursing
them for lack or insufficiency of effectiveness data would
negate these devices to patients and hamper the overall inno-
vation process in this area; b) reimbursing them at the price
claimed by themanufacturer would imply tomake a decision
on their price only on subjective grounds or by purely nego-
tiable criteria, thus failing to apply the value-for-money prin-
ciple. The application of a payment-by-results procedure (as
described in the present report) therefore seems to be an ap-
propriate solution to this problem.
Our article is not intended to discuss the local methods
of payment that could be set up by individual institutions
within the boundaries of the payment-by-results approach.
Nevertheless, because this approach requires that health is
purchased a posteriori (ie, after it has already been gener-
ated), the simplest solution is that the manufacturer of the
LVAD is paid monthly for an amount of money equal to
the MCV multiplied by the number of patients being
treated after their bLE with the device during that month.
The average economic amount per device recognized by
our analysis was, as expected, the result of a series of indi-
vidual values distributed over a wide range (Figure 1). Var-
iations over opposite extremes ranging from V0 to more
than V250,000 pose an extraordinarily strong challenge to
both the health care system and the manufacturer in which
the outcome of the individual patient (along with his or
her undisputable end point of survival) represents the key
factor for the whole mechanism of payment.
The payment-by-results approach explicitly requires to
change the way the hospital (or third payer) reimburses the
vendor because, for example, the latter would be paid
monthly at a rate of approximately 5000 euros per month
for every month lived by the patient beyond his or her ex-
pected life expectancy without implant. These regular repet-
itive payments are already a standard in other areas of
medicine, for example, home dialysis.22
It is true the first payment would be received by the vendor
only when as many months have passed as is the patient’s
expected survival without implant (determined at baseline,
ie, at the time of the implant). Regardless of the method
for predicting the expected survival without implant (based
on either population average data8 or an individualized
model18), this lag in the initiation of the payments is in
full accordance with the risk-sharing nature of this form of
reimbursement. Of course, there would be no substantial dis-
tortion in the payment-by-results approach in the case of lo-
cal deals or negotiations wherein a small proportion of the
list price (eg, 10%) is paid to the vendor at the time of the
implant; this would prevent the extreme situation in which
the vendor provides the device to the hospital but ultimately
receives no payment at all for the device (ie, in cases of
therapeutic failures with postimplant survival less than the
patient’s expected survival without implant).ardiovascular Surgery c Volume 138, Number 2 483
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who could financially benefit more from a long-term success
in the payment-by-results method. These cases are, how-
ever, also ‘‘favorable’’ for the hospital because the patient’s
improvement in survival (which is paid for) does not have an
expected nature, but a real one.
In our proposal, life expectancy for patients without an
implanted LVAD is handled either as a median ‘‘popula-
tion’’ value drawn from the Kaplan–Meier curve (‘‘popula-
tion method’’) or as an individualized covariate-adjusted
estimate (‘‘individualized method’’) determined by the ap-
plication of the Seattle model (variables incorporated in
the Seattle model18 include gender, age, New York Heart
Association class, weight, ejection fraction, systolic blood
pressure, medications, and clinical chemistry data).
Thus, our approach does not have any intermediate option
between the first logical extreme where median survival is
not adjusted for any patient’s variable (ie, no adjustment
for gender, no adjustment for age, and so on) and the other
logical extreme where survival is adjusted for an array of
patient-related variables (ie, the 8 variables of the Seattle
model mentioned above).
Finally, it should be noted that survival data from Heart-
Mate device implants include few female patients8 so that
our ‘‘population method’’ could understate to some extent
the baseline survival one might see today with current treat-
ment modality in patients without an implanted LVAD with
class IV heart failure.
Our sensitivity analysis was interesting particularly in re-
gard to the effect of utility. A close scrutiny of the results
shown in Table 1 supports the view that the average reim-
bursement associated with the utility of 0.809 (V66,683) is
actually representative of ‘‘real’’ outcomes so that one can
even postulate that the average of V66,683 might paradoxi-
cally be ‘‘more basecase’’ than our basecase analysis.
One question arises on whether or not the economic coun-
tervalue of the benefit (determined according to Equation 1)
should be intended to cover only the cost of the device (first
case) or, alternatively, all the main sources of incremental
cost (second case) inclusive of the cost of the device and
the cost of surgery (approximately V50,00023).
In the first case, if one makes reference to total costs and
total reimbursements over a representative series of the
number of patients receiving implants, the total cost for
the number of devices at their current real price (total cost
¼ V75,000 3 N) is likely to be fully covered by the reim-
bursements determined according to our procedure (total
reimbursement ¼ sum of N unpredictable individual reim-
bursements whose average is expected to be V82,426,
ie, V82,426 3 N).
In the second case, the total incremental cost for the num-
ber of patients receiving implants (total cost¼V75,0003N
þ V50,000 3 N ¼ V125,000 3 N) would not be fully
covered by the reimbursements (total reimbursements ¼484 The Journal of Thoracic and Cardiovascular SurV82,4263N), and so a certain proportion of the total incre-
mental cost (ie, 34% according to the above figures) would
remain without coverage. Interestingly enough, the local
health policy of our region of Tuscany currently seems to
be in favor of the ‘‘first’’ case.
CONCLUSIONS
This report delineates an innovative procedure for the eco-
nomic management of LVADs that seems to be without
alternatives to ensure an appropriate allocation of economic
resources, at least in this area of invasive cardiology. In Italy
and many other countries, one factor that can increase the
willingness of vendors to accept these innovative payment
schemes is that LVADs are not presently included in any
diagnosis-related group capable of covering their high
acquisition cost. So, these innovative payment approaches
can be the only way to open the market to these new devices
and to allow patients to have access to this form of potential
therapeutic advance.
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